Cancer drug development comes of age

Cancer impacts people of all ages.
New treatments should too.

Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. We are a unique company created to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. Our distinctive approach, together with our trusted network of pediatric oncology investigators, gives us an unparalleled ability to advance promising discoveries for patients of any age. We are ready to pursue the full potential of our therapies to improve the greatest number of lives as quickly as possible.

Calling all pediatric oncologists

Join our community of pediatric oncology investigators intent on advancing treatments for childhood cancer.

Promising pipeline

Explore our clinical-stage portfolio aimed at improving cancer treatments for both children and adults.

Ingenious teammates wanted

Team up with bold thinkers who are passionate about making a real difference in the way we treat cancer.


In the news

Nov 19, 2020

In PNOC014, an ongoing Phase 1 Pacific Pediatric Neuro-Oncology Consortium (PNOC) network study sponsored by the Dana-Farber… read more

Sep 23, 2020

Dr. Jeremy Bender, former VP of Corporate Development at Gilead and COO of Tizona, joins as Chief… read more

May 21, 2020

Inspired and enabled by the pediatric oncology community, Day One prioritizes promising new medicines that can be… read more